for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

現在値

72.20USD

変化

-1.90(-2.56%)

出来高

6,040,361

本日のレンジ

71.41

 - 

75.00

52週レンジ

12.47

 - 

95.21

∙ 約20分前の相場を表示しています。

適時開示

Fauci Says Can't Abandon Public Health Measures Even After COVID-19 Vaccines

Aug 7 (Reuters) - Anthony Fauci: :NIH'S FAUCI SAYS TRIAL FOR MODERNA CORONAVIRUS VACCINE LIKELY TO BE FULLY ENROLLED IN EARLY FALL: BROWN UNIVERSITY WEBINAR.NIH'S FAUCI EXPECTS COULD HAVE ANSWERS FROM MODERNA CORONAVIRUS VACCINE TRIAL AS SOON AS NOV/DEC: BROWN UNIVERSITY WEBINAR.FAUCI SAYS POTENTIAL CORONAVIRUS VACCINES LIKELY TO BE 50-60% EFFECTIVE, SO CAN'T ABANDON PUBLIC HEALTH MEASURES: BROWN UNIVERSITY WEBINAR.

Moderna Reports Q2 Revenue Of $66.4 Mln

Aug 5 (Reuters) - Moderna Inc <MRNA.O>::MODERNA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q2 REVENUE $66.4 MILLION VERSUS $13.1 MILLION.Q2 REVENUE ESTIMATE $27.4 MILLION -- REFINITIV IBES DATA.UPDATES 2020 GUIDANCE TO REFLECT INVESTMENTS INTO MRNA-1273.ENDED QUARTER WITH $3.1 BILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.RECEIVED APPROXIMATELY $400 MILLION OF CUSTOMER DEPOSITS AS OF JULY 31, 2020 FOR POTENTIAL SUPPLY OF MRNA-1273.UPDATES 2020 GUIDANCE TO REFLECT INVESTMENTS INTO MRNA-1273.PHASE 3 STUDY OF MRNA-1273 BEING CONDUCTED IN COLLABORATION WITH NIH AND BARDA ON TRACK TO COMPLETE ENROLLMENT IN SEPTEMBER 2020.NOW EXPECTS NET CASH USED IN OPERATING ACTIVITIES AND FOR PURCHASES OF PROPERTY AND EQUIPMENT TO BE BETWEEN $0.65 TO $0.85 BILLION.QTRLY LOSS PER SHARE 31 CENTS.MODERNA - COLLABORATION REVENUE RISE MAINLY ATTRIBUTABLE TO AN INCREASE IN REVENUE IN Q2, PARTICULARLY FROM ASTRAZENECA.Q2 EARNINGS PER SHARE VIEW $-0.35 -- REFINITIV IBES DATA.

Moderna Announces Resignation Of Dr. Elizabeth Nabel From Board Of Directors

July 30 (Reuters) - Moderna Inc <MRNA.O>::MODERNA ANNOUNCES RESIGNATION OF DR. ELIZABETH NABEL FROM BOARD OF DIRECTORS.MODERNA INC - ELIZABETH NABEL IS PRESIDENT OF BRIGHAM AND WOMEN'S HOSPITAL, WHICH IS PARTICIPATING AS A TRIAL SITE IN PHASE 3 TRIAL OF MRNA-1273.MODERNA INC - ACCEPTED BETSY'S RESIGNATION OUT OF AN ABUNDANCE OF CAUTION TO AVOID ANY POTENTIAL OR EVEN APPARENT CONFLICT OF INTEREST.

Moderna Announces Phase 3 Cove Study Of MRNA Vaccine Against Covid-19 Begins

July 27 (Reuters) - Moderna Inc <MRNA.O>::MODERNA ANNOUNCES PHASE 3 COVE STUDY OF MRNA VACCINE AGAINST COVID-19 (MRNA-1273) BEGINS.MODERNA INC -.MODERNA INC - PHASE 3 STUDY BEING CONDUCTED IN COLLABORATION WITH NIH AND BARDA.MODERNA INC - EXPECTED TO ENROLL 30,000 PARTICIPANTS IN U.S..MODERNA INC - REMAINS ON TRACK TO BE ABLE TO DELIVER APPROXIMATELY 500 MILLION DOSES PER YEAR.

Moderna Announces Expansion Of Barda Agreement To Support Larger Phase 3 Program For Vaccine Against COVID-19

July 26 (Reuters) - Moderna Inc <MRNA.O>::MODERNA ANNOUNCES EXPANSION OF BARDA AGREEMENT TO SUPPORT LARGER PHASE 3 PROGRAM FOR VACCINE (MRNA-1273) AGAINST COVID-19.MODERNA-ADDITIONAL FUNDING TO SUPPORT EXPANDED MRNA-1273 CLINICAL DEVELOPMENT PLAN INCLUDING 30,000 PARTICIPANT PHASE 3 COVE STUDY CONDUCTED WITH NIH.MODERNA-ADDITIONAL FUND OF UP TO $472 MILLION TO SUPPORT PHASE 3 STUDY OF CO’S MRNA VACCINE CANDIDATE AGAINST COVID-19.THE TOTAL VALUE OF AWARD IS NOW APPROXIMATELY $955 MILLION.MODERNA - CO REMAINS ON TRACK TO BE ABLE TO DELIVER ABOUT 500 MILLION DOSES PER YEAR, AND POSSIBLY UP TO 1 BILLION DOSES PER YEAR, BEGINNING IN 2021.

Moderna Issues Statement On Patent Trial And Appeal Board Ruling

July 24 (Reuters) - Moderna Inc <MRNA.O>::STATEMENT FROM MODERNA ON PATENT TRIAL AND APPEAL BOARD (PTAB) RULING.MODERNA INC - NOT AWARE OF ANY SIGNIFICANT INTELLECTUAL PROPERTY IMPEDIMENTS FOR ANY PRODUCTS CO INTENDS TO COMMERCIALIZE, INCLUDING MRNA-1273..MODERNA - RECENT PTAB RULING RELATES TO CO'S CHALLENGE TO CERTAIN LEGACY PATENTS HELD BY ARBUTUS, COMMENCED WELL BEFORE DEVELOPMENT OF MRNA-1273.MODERNA INC - CO'S LNP FORMULA USED TO MANUFACTURE MRNA-1273 IS NOT COVERED BY ARBUTUS PATENTS.

Medidata Supports Moderna In COVID-19 Vaccine Clinical Trials

July 23 (Reuters) - Dassault Systemes SE <DAST.PA>::MEDIDATA SUPPORTS MODERNA'S COVID-19 VACCINE CLINICAL TRIALS WITH RAVE CLINICAL CLOUD PLATFORM.MEDIDATA IS COLLABORATING WITH MODERNA, INC. TO SUPPORT CLINICAL TRIALS OF MRNA-1273, MODERNA'S COVID-19 VACCINE CANDIDATE.

Moderna Executive Says Will Not Sell Coronavirus Vaccine At Cost Of Production At Congressional Hearing

July 21 (Reuters) - House Subcommittee on Oversight and Investigations::MODERNA EXECUTIVE SAYS WE WILL NOT SELL CORONAVIRUS VACCINE AT COST OF PRODUCTION : CONGRESSIONAL HEARING.MERCK & CO EXECUTIVE SAYS WE WILL NOT SELL CORONAVIRUS VACCINE AT COST OF PRODUCTION : CONGRESSIONAL HEARING.MERCK EXECUTIVE SAYS MAY END UP WITH MORE THAN 1 CORONAVIRUS VACCINE AS FIRST VACCINE MAY NOT BE BEST FOR SENIORS OR CHILDREN: CONGRESSIONAL HEARING.

NIH's Fauci says Moderna's vaccine very likely in phase three by end of month

July 9 (Reuters) - Moderna Inc <MRNA.O>::NIH's Fauci says Moderna's <<<<MRNA.O>>>> COVID-19 vaccine will very likely be going into advanced phase three clinical trials by the end of july.NIH's Fauci says hopes that by the end of this calendar year or the beginning of 2021 that we will have a COVID-19 vaccine.

Moderna And ROVI Announce Collaboration For OUS Fill-Finish Manufacturing Of Moderna's COVID-19 Vaccine Candidate

July 9 (Reuters) - Moderna Inc <MRNA.O>::MODERNA AND ROVI ANNOUNCE COLLABORATION FOR OUS FILL-FINISH MANUFACTURING OF MODERNA’S COVID-19 VACCINE CANDIDATE.MODERNA INC - ROVI WILL PROVIDE VIAL FILLING AND PACKAGING CAPACITY.MODERNA INC - MODERNA'S PHASE 3 STUDY OF APPROXIMATELY 30,000 PARTICIPANTS, IS EXPECTED TO BEGIN IN JULY 2020.MODERNA - COLLABORATION FOR LARGE-SCALE, COMMERCIAL FILL-FINISH MANUFACTURING OF MRNA VACCINE CANDIDATE AGAINST COVID-19 AT ROVI'S FACILITY IN MADRID.MODERNA AND ROVI ANNOUNCE COLLABORATION FOR OUS FILL-FINISH MANUFACTURING OF MODERNA'S COVID-19 VACCINE CANDIDATE.MODERNA - AGREEMENT ON VACCINE CANDIDATE INTENDED IN PRINCIPLE TO SUPPLY MARKETS OUTSIDE OF U.S. STARTING IN EARLY 2021.MODERNA INC - ROVI WILL ALSO HIRE ADDITIONAL STAFFING REQUIRED TO SUPPORT MANUFACTURING OPERATIONS AND PRODUCTION.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up